Morgan Stanley Keeps Their Hold Rating on Prelude Therapeutics (PRLD)

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Prelude Therapeutics (PRLDResearch Report) today and set a price target of $10.00. The company’s shares opened today at $7.98.

According to TipRanks, Hung is a 5-star analyst with an average return of 23.8% and a 56.52% success rate. Hung covers the Healthcare sector, focusing on stocks such as Rubius Therapeutics, Prelude Therapeutics, and Neurocrine.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prelude Therapeutics with a $13.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $16.49 and a one-year low of $3.87. Currently, Prelude Therapeutics has an average volume of 68.94K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Read More on PRLD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More